Table 2.
The classification performance within TCGA datasets (%).
| Cancer type | Accuracy | Sensitivity | Specificity | AUC |
|---|---|---|---|---|
| Gastric cancere | 97 | 86 | 99 | 97 |
| Colon cancere | 96 | 96 | 97 | 97 |
| Endometrial cancere | 90 | 86 | 92 | 93 |
| Pan-cancer (all samples)e | 95 | 85 | 97 | 95 |
| Pan-cancer (80% of samples)e | 94 | 88 | 97 | 97 |
| Pan-cancer (20% of samples)f | 94 | 86 | 96 | 95 |
| Accuracy | |||
| Training | Test | ||
| Gastric cancer | Colon cancer | Endometrial cancer | |
| Gastric cancer | 97 | 87 | |
| Colon cancer | 92 | 80 | |
| Endometrial cancer | 82 | 85 | |
| Sensitivity | |||
| Test |
|||
| Training | Gastric cancer | Colon cancer | Endometrial cancer |
| Gastric cancer | 83 | 63 | |
| Colon cancer | 80 | 62 | |
| Endometrial cancer | 94 | 83 | |
| Specificity | |||
| Test |
|||
| Training | Gastric cancer | Colon cancer | Endometrial cancer |
| Gastric cancer | 100 | 100 | |
| Colon cancer | 95 | 90 | |
| Endometrial cancer | 79 | 86 | |
| AUC | |||
| Test |
|||
| Training | Gastric cancer | Colon cancer | Endometrial cancer |
| Gastric cancer | 94 | 92 | |
| Colon cancer | 95 | 83 | |
| Endometrial cancer | 95 | 87 | |
Note:
e
10-fold cross validation.
f
Validation in the independent test set.